Sentences with phrase «chemotherapy alone»

The website reported that patients who have the typical standard of care, chemotherapy alone, live an average of 12 to 18 months.

In trails, researchers are able to extend remission 9 months longer than with chemotherapy alone.

The median survival in dogs treated with early chemotherapy alone (cisplatin or carboplatin) at Purdue University was 130 days.

However, with chemotherapy alone, most dogs eventually relapse within two years.

When results of treatment with standard chemotherapy alone versus chemotherapy plus Herceptin were compared, it was found that tumors shrank at least 50 percent in half the women getting chemotherapy with Herceptin, compared with one - third of women receiving chemotherapy alone.

Those who received standard chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just over 14 months without their disease progressing compared with about 10 months for those receiving standard chemotherapy alone.

In the trial, patients who received Rydapt in combination with chemotherapy lived longer than patients who received chemotherapy alone, although a specific median survival rate could not be reliably estimated.

In addition, patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).

The study, published in November 2016 in The Lancet Oncology and presented with updated outcomes at the October 2017 World Conference on Lung Cancer in Yokohama, Japan, reported that 57 percent of patients receiving the combination therapy responded to treatment, whereas only 31 percent responded to chemotherapy alone.

In addition, although a survival benefit was not observed upon initial data analysis, results presented at the conference showed that those treated with the combination therapy appeared to live longer than those treated with chemotherapy alone.

Chemotherapy alone can, in some cases, achieve complete remission, where the patient is cured and the cancer does not return.

Led by Leena Gandhi, MD, PhD, associate professor of medicine and director of thoracic medical oncology, researchers from the KEYNOTE - 021 study demonstrated for the first time that combining an immune checkpoint inhibitor — in this case, pembrolizumab — with a platinum - doublet chemotherapy regimen might be more effective than chemotherapy alone as first - line treatment for advanced, non-squamous NSCLC.

The trial actually enrolled 938 patients with recurrent advanced NSCLC; physicians initially chose pemetrexed or docetaxel for patients, after which patients were randomized to either chemotherapy alone or in addition to a cetuximab regimen.

The treatment resulted in a median overall survival (OS) of longer than 3 years in both arms of the trial (median OS, 38.2 months for irradiation vs 36.6 months for nonmyeloablating chemotherapy alone; hazard ratio, 1.11 [95 % CI, 0.65 — 1.91]-RRB-.

In a comparison group of 56 patients who got standard chemotherapy alone, only half were still alive at the two - year mark.

Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

Patients with head and neck cancer seldom survive for longer than six months to one year when treated with chemotherapy alone.

The New EPOC study, published in The Lancet Oncology and funded by Cancer Research UK, evaluated whether the drug cetuximab and chemotherapy together worked better than chemotherapy alone as a treatment in addition to surgery for people with bowel cancer that had spread to the liver but could be surgically removed.

The other group received gemcitabine chemotherapy alone.

They found this was on average 14.1 months in the group having chemotherapy and cetuximab compared to 20.5 months in the group having chemotherapy alone.

«This is a promising treatment option that may prove not only to be more effective than chemotherapy alone prior to surgery, it may also be better than chemotherapy and standard radiation,» said lead study author Kimmen Quan, MD, a radiation oncologist at the University of Pittsburgh Medical Center.

(In clinical trials, HER2 - positive patients receiving Herceptin and standard combination chemotherapy had a 52 percent decrease in disease recurrence compared with patients treated with chemotherapy alone.)

The period of time before ovarian cancer recurred (called progression - free survival) improved by nearly 3.5 months with the additional drug (13.8 months compared with 10.4 months for the woman on chemotherapy alone).

Median overall survival for woman in the chemotherapy plus bevacizumab treatment was 42.2 months, compared with 37.3 for those receiving chemotherapy alone.

Because the vaccine causes the body to mount an immune response directed against a unique tumor, the therapy is much more effective than gene - targeted or more general chemotherapy alone.

The addition of necitumumab to gemcitabine and cisplatin chemotherapy improved overall survival and progression free survival by 21 % and 16 %, respectively, as compared to chemotherapy alone in patients whose tumours expressed the EGFR protein.

Specifically, they found that chemotherapy alone leads to two types of dormant cancer cells that are not killed outright and become resistant to additional chemotherapy, but when combined with immunotherapy, a majority of dormant cells also is destroyed.

Results suggest tumours with multiple wild - type KRAS, NRAS, BRAF and PIK3CA genes are likely to benefit from chemotherapy plus cetuximab and to demonstrate significantly better progression - free survival, response rate and overall survival than with chemotherapy alone,» commented Ciardiello.

The interim analysis found a median progression - free survival rate of 9.7 months with consolidative radiation therapy followed by chemotherapy, versus 3.5 months for maintenance chemotherapy alone (p = 0.01; Hazard Ratio (HR) = 0.304, 95 % CI 0.113 - 0.815).

Although the vaccine alone did not increase two - year survival rates beyond 8 percent, and chemotherapy alone had never increased survival beyond 8 percent either, when chemo was given to previously vaccinated patients, the survival curve began to go up.

«The data show that treatment with pembrolizumab and chemotherapy together is more effective than chemotherapy alone,» says Gandhi.

Working with mouse models of cancer, they demonstrated how treatment with antibiotics on top of chemotherapy may be significantly superior to treatment with chemotherapy alone.

All had levels of residual disease that indicated a poor initial response to chemotherapy alone, including nine with MRD levels of 25 percent or more.

April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.

In a late - stage trial, Darzalex combined with Velcade and chemotherapy slashed patients» risk of worsening disease or death by a stunning 61 % compared with the results for Velcade and chemotherapy alone.

«More than twice the number of patients [were] still living at the end of the study after receiving IMAB362 plus chemotherapy compared to chemotherapy alone,» according to Ganymed CEO Özlem Türeci, with patients showing the highest level of that protein biomarker responding best to the treatment.

Not exact matches

Tests showed that combining mTOR inhibitors with chemotherapy was far more effective at treating leukemia than when the inhibitors or chemotherapy were used as stand - alone treatments.

A total of 46 patients received GO alone or in combination with conventional chemotherapy.

Seventeen patients received GO alone when MRD was detected after two rounds of chemotherapy with the drugs cytarabine, daunorubicin and etoposide.

They compared the effectiveness of the combination treatments with just treating the leukemia by chemotherapy or inhibitors alone.

In a clinical trial published in June, melanoma patients who received ipilimumab combined with chemotherapy gained a precious extra few months» survival compared with those who received chemo alone, and the treatment nearly doubled the number of patients still living after three years.

We identified patients with mutations that predict phenomenal outcomes in the disease; this is a group of women with endometrial cancer who won't need the financial, physical or emotional toll of chemotherapy at all — they're patients who are probably cured by surgery alone.

Chemotherapy and radiotherapy alone are relatively unsuccessful in treating the disease, and while surgery to remove the tumour offers the best chance of survival, most patients are diagnosed when the cancer has already spread to other organs.

Administering a combination of Abraxane ® and Intralipid ® results in less of toxicity of the chemotherapy drug in the kidney (bottom row) than administering Abraxane ® alone (top row).

Estimated overall survival at five years was 14.5 % higher for patients who received chemotherapy and radiation compared to patients who received radiation alone (86.1 % versus 71.6 %).

The study demonstrated that a group of trial participants with low 21 - gene recurrence score (Oncotype DX ® Recurrence Score ®) results of 10 or less who received hormonal therapy alone without chemotherapy had less than a one percent chance of distant recurrence at five years.

They confirmed this by showing that tumor growth was reduced in mice treated with an antibody drug that targets TIM - 3 and the chemotherapy agent paclitaxel, as compared to treatment with paclitaxel alone.

In a study presented today at a meeting of women's cancer specialists, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.

Most relapses occur within five years, and at ten years local relapse rates were 22.4 % (CI 17.1 - 27.6) with radiotherapy alone, 11.8 % (7.8 - 15.8 %) with neoadjuvant radiotherapy - chemotherapy, 14.5 % (10.1 - 18.9 %) with radiotherapy and adjuvant chemotherapy, and 11.7 % (7.7 - 15.6 %) with both adjuvant and neoadjuvant chemotherapy (p = 0.0017).